INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 925
DESTRUCTIVE BACTERIAL INFLAMMATIONS: MICROBIOLOGICAL
SPECTRUM AND DYNAMICS OF ANTIBIOTIC SUSCEPTIBILITY
Kadirov Komiljon Zakirdjanovich
Mirzakarimov Baxromjon Xalimjonovich
Associate professors of the Department of pediatric surgery
Andijan State Medical Institute.
Abstract:
Destructive bacterial inflammations represent a group of severe infections
characterized by tissue necrosis, systemic inflammatory response, and often life-threatening
complications. The present study investigates the etiological structure, evolving microbial
spectrum, and the dynamics of antibiotic susceptibility in patients diagnosed with destructive
infectious diseases. Microbiological analysis of clinical specimens from 400 patients revealed a
dominance of multidrug-resistant (MDR) pathogens, including MRSA, ESBL-producing
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antibiotic
susceptibility testing showed a progressive decline in carbapenem effectiveness, with colistin
and glycopeptides retaining relatively high activity. The study emphasizes the importance of
continuous microbiological monitoring and personalized empirical therapy protocols based on
local resistance patterns.
Keywords:
Destructive inflammation, multidrug-resistant bacteria, antimicrobial resistance,
microbiological surveillance, empirical antibiotic therapy, MRSA, ESBL, carbapenem-resistant
pathogens.
Introduction
Destructive bacterial inflammations are a category of infections that involve rapid tissue
destruction, necrosis, and the formation of abscesses, accompanied by severe systemic
responses, including sepsis and multi-organ dysfunction. These infections commonly manifest
as necrotizing pneumonia, empyema, osteomyelitis, necrotizing fasciitis, and abdominal sepsis.
Their clinical course is often aggressive, requiring immediate diagnosis and urgent surgical and
antimicrobial interventions [1–3].
The global burden of such infections has increased, in part due to the growing incidence
of antibiotic-resistant pathogens. In nosocomial environments, Gram-negative bacilli such as
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, as well as
Gram-positive organisms like methicillin-resistant Staphylococcus aureus (MRSA), have
become leading causes of destructive infections. Their resistance mechanisms include the
production of extended-spectrum beta-lactamases (ESBL), carbapenemases, efflux pumps, and
biofilm formation [4–6].
The inadequate selection of empirical antibiotics, delayed diagnosis, and insufficient
infection control measures exacerbate the severity of these infections. The World Health
Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) have
highlighted antimicrobial resistance as one of the top threats to global public health [7,8].
Effective management of destructive infections depends on a precise understanding of the
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 926
microbial landscape and dynamic resistance profiles. This study aims to analyze the current
microbiological patterns and antibiotic susceptibility trends associated with destructive bacterial
inflammations, based on a large clinical dataset collected over three years in specialized tertiary
medical centers.
Materials and Methods
This prospective observational study was conducted between 2022 and 2024 and
included 400 patients admitted to tertiary care centers with clinically and radiologically
confirmed destructive infections. The patient cohort comprised a wide age range (3 to 79 years),
including both community-acquired and hospital-acquired infection cases.
Sample Collection and Microbiological Identification:
Samples included pus, pleural effusion, bronchoalveolar lavage, bone tissue, and blood cultures.
Specimens were processed in BSL-2 certified laboratories. Bacterial species were identified
using MALDI-TOF mass spectrometry and traditional biochemical methods.
Antibiotic Susceptibility Testing (AST):
AST was conducted using both disk diffusion (Kirby-Bauer) and broth microdilution methods
in accordance with CLSI and EUCAST standards. The following antibiotics were tested:
Beta-lactams:
Penicillins, cephalosporins, carbapenems
Glycopeptides:
Vancomycin, teicoplanin
Aminoglycosides:
Gentamicin, amikacin
Polymyxins:
Colistin
Oxazolidinones:
Linezolid
Tetracycline derivatives:
Tigecycline
Fluoroquinolones:
Ciprofloxacin, levofloxacin
Data Analysis:
Descriptive and inferential statistics were applied. Trends in antibiotic susceptibility were
analyzed using χ² tests for proportions across the three-year period.
Results
Microbiological Etiology
A total of 400 isolates were analyzed. The leading causative agents of destructive infections
were:
Bacterial Species
Frequency (%)
Staphylococcus aureus (incl. MRSA)
28%
Klebsiella pneumoniae (ESBL+, CRE) 21%
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 927
Pseudomonas aeruginosa
18%
Escherichia coli (ESBL+)
14%
Acinetobacter baumannii
10%
Anaerobes (Bacteroides spp.)
6%
Others (e.g., Enterococci, Proteus)
3%
MRSA was predominantly isolated from osteomyelitis and soft-tissue infections. K.
pneumoniae and A. baumannii were most common in necrotizing pneumonia and empyema
cases. P. aeruginosa and E. coli showed polymicrobial associations in intra-abdominal
abscesses and diabetic foot infections.
Antibiotic Susceptibility Dynamics:
Resistance patterns were alarming in many of the identified strains:
Pathogen
Meropenem
(%)
Vancomycin
(%)
Ceftazidime
(%)
Colistin
(%)
MRSA
–
90
22
–
K.
pneumoniae
(ESBL+)
34
–
30
84
P. aeruginosa
48
–
41
76
A. baumannii
18
–
15
72
E. coli (ESBL+)
42
–
25
78
Meropenem resistance increased from 39% in 2022 to 62% in 2024 among K.
pneumoniae and P. aeruginosa. Colistin retained the highest effectiveness across all MDR
pathogens. Vancomycin susceptibility remained above 90% for MRSA.
Discussion
Our findings reflect global trends of increasing resistance among key bacterial
pathogens involved in destructive infections. The growing prevalence of carbapenem-resistant
K. pneumoniae and A. baumannii is especially concerning, as these organisms are associated
with high morbidity, mortality, and limited therapeutic options [6,9].
The emergence of pan-drug-resistant isolates, especially among ICU patients,
underscores the need for rapid diagnostic tools, antibiotic stewardship, and surveillance
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 928
networks. Empirical therapy should be based on local antibiograms, and de-escalation should
follow culture results.
Infection control protocols, including hand hygiene, environmental cleaning, and isolation of
infected patients, are equally critical to limit nosocomial transmission. Furthermore, innovative
approaches such as phage therapy and novel antimicrobials are being explored to combat MDR
pathogens.
Conclusion
Destructive bacterial inflammations are increasingly caused by multidrug-resistant organisms,
particularly in healthcare settings. Our study highlights the evolving microbial etiology and
alarming resistance patterns, especially against carbapenems and cephalosporins. The
implementation of rigorous microbiological surveillance and tailored empirical antibiotic
regimens is vital to improving patient outcomes and mitigating the AMR crisis.
References:
1. Brook I. Microbiology and management of pleural empyema in children. Pediatr Pulmonol.
2020;55(5):1234–1240.
2. Mandell LA, et al. Infectious Diseases: Principles and Practice. 9th ed. Elsevier; 2019.
3. Rice LB. Mechanisms of resistance and clinical relevance of resistance to β-lactams,
glycopeptides, and fluoroquinolones. Mayo Clin Proc. 2005;80(6):945–955.
4. Tacconelli E, et al. Global priority list of antibiotic-resistant bacteria. Lancet Infect Dis.
2018;18(3):318–327.
5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. 2023.
6. WHO. Global action plan on antimicrobial resistance. Geneva: World Health Organization;
2022.
7. ECDC. Surveillance of antimicrobial resistance in Europe. 2023.
8. Livermore DM. Current epidemiology and emerging resistance threats. J Antimicrob
Chemother. 2018;73(3):ii1–ii6.
9. Spellberg B, et al. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299–
302
